CNS Pharmaceuticals, Inc. (CNSP)

New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCESS Newswire / February 17, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the Company's recently appointed President and Chief Executive officer, Rami Levin, in close alignment with the Board of Directors, has recruited key members to his new executive team. These new appointments, which will be effective March 2, 2026, will help drive the Company's evolution.

Shares of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP - Get Free Report) fell 11.2% during mid-day trading on Wednesday. The company traded as low as $3.63 and last traded at $3.63. 32,885 shares were traded during trading, a decline of 58% from the average session volume of 78,209 shares. The stock had previously closed at $4.09.

Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS Pharmaceuticals Strategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term Value Creation HOUSTON, TX / ACCESS Newswire / January 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today issued a Letter to Shareholders from its newly appointed President and Chief Executive Officer, Rami Levin. Dear Fellow Shareholders, I am honored to write to you for the first time in my role as President and Chief Executive Officer of CNS Pharmaceuticals.

Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced John Climaco has stepped down as Chief Executive Officer of CNS Pharmaceuticals and Rami Levin, MBA, has been appointed as President & Chief Executive Officer. Mr. Levin brings nearly 30 years of global leadership experience across oncology, neurology, rare diseases, endocrinology, and cell and gene therapy, with a proven track record of scaling organizations, advancing late-stage clinical programs, and driving transformative value creation.

CNS Pharmaceuticals, Inc. ( CNSP ) Shareholder/Analyst Call November 17, 2025 12:00 PM EST Company Participants John Climaco - CEO, President & Director Christopher Downs - Chief Financial Officer Presentation John Climaco CEO, President & Director Welcome, everyone. The Annual Meeting of the Stockholders of CNS Pharmaceuticals, Inc. is hereby convened and called to order.

Cash expected to fund operations into the second half of 2026 Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the blood-brain barrier, potentially enhancing efficacy for patients Lead program, TPI 287, progressing toward Phase 2 study for treatment of glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer, with a median survival of only around 15 months from the time of diagnosis HOUSTON, TX / ACCESS Newswire / November 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the third quarter ended September 30, 2025 and provided a corporate update. "As we head into the final quarter of the year, our mission remains centered on delivering meaningful developments for patients battling brain and CNS cancers.

HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that three abstracts have been selected for poster presentation at the 2025 SNO Annual Meeting being held November 19-23, 2025 in Honolulu, HI. Details of the poster presentations are as follows: Title: Activity of Berubicin against Pediatric Diffuse Midline Glioma (DMG) cells: Preliminary data and future possibilities Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals Abstract Code: EXTH-133 Date and Time: Friday, November 21, 2025 at 11:45 am - 1:05 pm HST Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III Title: TPI 287, which in combination with Bevacizumab (BEV) has shown activity in patients with glioblastoma (GBM) after prior therapy, will be evaluated in a Phase 2 trial as well as in other CNS diseases Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals Abstract Code: CTNI-70 Date and Time: Saturday, November 22, 2025 at 11:45 am - 1:05 pm HST Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III Title: Primary results of the randomized clinical trial of Berubicin vs Lomustine in patients with glioblastoma after failure of primary therapy: Data analysis and future possibilities Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals Abstract Code: CTNI-74 Date and Time: Saturday, November 22, 2025 at 11:30 am - 12:45 pm HST Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III For more information about the event, please visit the meeting website.

HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.

Strong cash position of $12.1 million expected to fund operations into the second half of 2026 Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / August 15, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the second quarter ended June 30, 2025 and provided a corporate update. "Every decision we make is grounded in our science and driven by a sense of urgency and responsibility to the patients and families counting on us for better outcomes.

- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025 Details for the presentation are as follows: Date and Time: Tuesday, August 19, 2025 at 2:40 PM ET Presenter: John Climaco, Chief Executive Officer Registration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing.

– Video webcast now available on-demand  HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. As part of the event, Mr.

HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-12 reverse split of its common stock. Beginning on July 22, 2025, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP" but will trade under the following new CUSIP number: 18978H508.

HOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals recently participated in a Virtual Investor CEO Connect segment. As part of this segment, Mr.

Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, a founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, who specializes in the comprehensive care of brain and spine tumor patients who are battling both primary and metastatic tumors. As part of the segment, Dr. Dunbar discussed the patient journey and current treatment landscape for Glioblastoma Multiforme and CNS Pharma's lead product candidate, TPI 287, and its potential as a treatment for GBM as well as for future indications in metastatic tumors.

In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that Sandra Silberman, M.D., Ph.D., Chief Medical Officer of CNS Pharmaceuticals, will present at the Lenox Hill Hospital, Department of Neurosurgery's Brain Tumor Biotech Summit being held on June 5, 2025 in New York, NY.

Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / May 16, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. "Our company remains focused as tightly as ever on neuro-oncology drug development.